Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seema Kumar

Showing results (141-150 of 143) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 143 results.
Bioanalysis|January 29, 2021
2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (<u>Part 2A</u> - Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation <u>Part 2B</u> - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)Susan Spitz, Yan Zhang, Sally Fischer, et al.
Journal of Translational Medicine|June 23, 2023
Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)Filippo Pinto E Vairo, Jennifer L Kemppainen, Carolyn R Rohrer Vitek, et al.
Journal of Translational Medicine|April 30, 2024
Correction: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)Filippo Pinto E Vairo, Jennifer L Kemppainen, Carolyn R Rohrer Vitek, et al.
Pageof 15

Showing results (141-150 of 143) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 143 results.
Bioanalysis|January 29, 2021
2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback (<u>Part 2A</u> - Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation <u>Part 2B</u> - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)Susan Spitz, Yan Zhang, Sally Fischer, et al.
Journal of Translational Medicine|June 23, 2023
Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)Filippo Pinto E Vairo, Jennifer L Kemppainen, Carolyn R Rohrer Vitek, et al.
Journal of Translational Medicine|April 30, 2024
Correction: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)Filippo Pinto E Vairo, Jennifer L Kemppainen, Carolyn R Rohrer Vitek, et al.
Pageof 15